ArticleThe Journal of antimicrobial chemotherapy2020
Macrolide resistance and molecular typing of Mycoplasma pneumoniae infections during a 4 year period in Spain.
Article in The Journal of antimicrobial chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 30 citations in OpenAlex.
- Predicting macrolide resistance in pediatric Mycoplasma pneumoniae pneumonia: A machine learning modeling study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- AgeFrontiers in pediatrics · 2026Article
- The impact of the COVID-19 pandemic on the epidemiology, clinical manifestations and molecular characteristics ofFrontiers in immunology · 2026Review
- Influence of Mycoplasma Resistance Genes on Pediatric Mycoplasma Pneumonia Treatment and Determinants for Second-line Antimicrobial Adjustment.Combinatorial chemistry & high throughput screening · 2026Article
- Host inflammatory markers and MLVA profiling for risk assessment of severe pediatricFrontiers in cellular and infection microbiology · 2026Article
- Navigating the outbreak: a comprehensive analysis of pediatricMicrobiology spectrum · 2025Article
- Synergistic impact of macrolide resistance and H3N2 infection onMicrobiology spectrum · 2025Article
- Recent Macrolide Resistance Pattern of Mycoplasma Pneumonia in the World: A Systematic Review and Meta-Analysis.Iranian journal of public health · 2025Review
- Epidemiological characteristics of severe community-acquired pneumonia in children admitted to two tertiary hospitals in Shihezi, Xinjiang Region, China in 2023: a cross-sectional analysis.Journal of thoracic disease · 2024Article
- Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.World journal of pediatrics : WJP · 2024Review
- Macrolide-resistantHeliyon · 2024Article
- [Macrolide-resistant Mycoplasma pneumoniae: Do we know the situation in Europe?]Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Review
- The molecular characteristics, diagnosis, and treatment of macrolide-resistantFrontiers in pediatrics · 2023Review
- The clinical significance of macrolide resistance in pediatricFrontiers in cellular and infection microbiology · 2023Article
- Recent Trend of Antimicrobial Susceptibility amongMicroorganisms · 2022Article
- Correlation between Mycoplasma pneumoniae drug resistance and clinical characteristics in bronchoalveolar lavage fluid of children with refractory Mycoplasma pneumoniae pneumonia.Italian journal of pediatrics · 2022Article
- Association of Intrauterine Microbes with Endometrial Factors in Intrauterine Adhesion Formation and after Medicine Treatment.Pathogens (Basel, Switzerland) · 2022Article
- Detection and Prevalence of Macrolide and Fluoroquinolone Resistance inAntibiotics (Basel, Switzerland) · 2022Article
- Recent Trends in the Epidemiology, Diagnosis, and Treatment of Macrolide-ResistantJournal of clinical medicine · 2022Review
- Development of a Rapid and Efficient RPA-CRISPR/Cas12a Assay forFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycoplasma pneumoniae (MP) causes community-acquired pneumonia affecting mainly children, and tends to produce cyclic outbreaks. The widespread use of macrolides is increasing resistance rates to these antibiotics. Molecular tools can help in diagnosis, typing and resistance detection, leading to better patient management.
objectivesTo assess the MP genotypes and resistance pattern circulating in our area while comparing serological and molecular diagnosis of MP.
methodsMolecular and serological diagnosis of MP was performed in 821 samples collected in Badalona (Barcelona, Spain) from 2013 to 2017. Multiple locus variable number tandem repeat analysis (MLVA) and macrolide resistance detection by pyrosequencing were performed in those cases positive by PCR. Presence of respiratory viruses and relevant clinical data were also recorded.
resultsMP was detected in 16.8% of cases by PCR, with an overall agreement with serology of 76%. Eleven different MLVA types were identified, with 4-5-7-2 (50.1%) and 3-5-6-2 (29.2%) being the most abundant, with the latter showing a seasonal increase during the study. A total of 8% of the strains harboured a point substitution associated with macrolide resistance, corresponding mainly to an A2063G 23S rRNA mutation and directly related to previous macrolide therapy. Analysis of respiratory viruses showed viral coinfections in most cases.
conclusionsSerological and molecular tools combined could improve MP diagnosis and the analysis of its infection patterns. Macrolide resistance is associated with previous therapy. Given that MP pneumonia usually resolves spontaneously, it should be reconsidered whether antibiotic treatment is suitable for all cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.